US company backs out of Elan deal
A US company today backed out of a €785m deal to buy the primary care business unit and two brand-name drugs from the Elan Corporation.
King Pharmaceuticals of Tennessee claimed in a statement that Elan committed “various breaches and misrepresentations” involving the asset purchase agreement signed by the companies on January 30.